BPMC (Blueprint Medicines Corporation) Earnings per share for the last four quarters

Public company logo of Blueprint Medicines Corp. (BPMC)

Blueprint Medicines ensures the seamless delivery of innovations through proven partners, expanding the presence of Ayvakit in oncology. The TTM EPS annual growth rate visualizes the financial trend, where the 10.40 metric indicates the profitability status. A monopoly position and patent protection for orphan drugs allow the company to flexibly manage pricing power, minimizing pressure from generics.

BPMC Blueprint Medicines Corporation Earnings per share for the last twelve months (02/11/2024 - 02/20/2024)

Blueprint Medicines Corp - analytical breakdowns and key metrics (BPMC)

- business market valuation indicators:
Fundamental valuation:Blueprint Medicines Corp. (BPMC)
Signature product of Blueprint Medicines Corp.

Year-over-year (YoY) EPS growth (TTM) measures the dynamics of rolling annual earnings per share, separating accounting reports from market value. By analyzing the current YoY TTM EPS growth rate, an investor assesses the real efficiency of capital generation between quarterly reports. This metric captures the rate of change in net income, reflecting the fundamental return of the business. For Blueprint Medicines (BPMC), this indicator confirms the monetization of its unique molecule discovery platform. The scalability of patents allows the company to transform approved drugs into global superprofits.

Competitor analysis for Blueprint Medicines

Earnings per share for the trailing year GMAB (Genmab US)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ideayabio.com|Earnings per share for the last twelve months Enliven Therapeutics, Inc. (ELVN)|ORIC (ORIC Pharmaceuticals, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) RLAY (Relay Therapeutics Inc)|Net earnings per share for the trailing year Nurix Pharma|Tyra Biosciences Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Verastem|GLUE (Monte Rosa Therapeutics) - Net earnings per share for the last 12 months|CGEM: Earnings per share for the last four quarters|IMRX (immuneering.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months C4 Tx CCCC|Net earnings per share (EPS TTM) BDTX|Repare Therapeutics Inc. - Earnings per share for the last 12 months|PMV Pharmaceuticals, Inc. - Net earnings per share for the last 12 months|Earnings per share for the trailing year KPTI|PPCB: Net earnings per share for the last 12 months|Cyclacel Pharmaceuticals - Earnings per share for the last four quarters|AADI: Net earnings per share (EPS TTM)|Aileron Therapeutics Inc - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months SpringWorks Therapeutics Inc. SWTX